»» Searching for " Aegerion "
 Related Search Tags:  Aegerion AEGR Nasdaq:AEGR Lomitapide LDL-C
Showing Results 1-1 of 1 |  Sort by:     
Page 1 of 1  |  Go to page   
Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Aegerion Pharmaceuticals Incorporated - AEGR - provided a clinical update on its lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial is consistent with data previously reported at the 26- and 56-week time points. According to the company, the data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks. Aegerion Pharmaceuticals’ Lomitapide is being evaluated for its ability to reduce low density lipoprotein (LDL-C) or bad cholesterol levels in patients with homozygous familial hypercholesterolemia. Aegerion Pharmaceuticals aspires to change the way rare, genetic lipid disorders are treated. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekerarnrn***********rnrnTHIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)rn
Aegerion (AEGR) Clinical...
Categories: Videos 
Added: 134 days ago
By: karmastock
Runtime: 1m12s
Views: 36
 | Comments: 0
Not yet rated
Page 1 of 1  |  Go to page   
About Us   |   Terms of Use   |   Privacy Policy   |   Copyright Notes   |   Contact Us   |   Help   |      |   Back to the top of this page
Copyright © 2006-2007 bongoTYube. All rights reserved.    | Page created in 0.0586 seconds.